PubMed Health⌕ Search

Biomedical subjects

E P Panchenko

Publications and source records attributed to E P Panchenko.

At least 19 recordsLinked to original sources
PubMed2006

[Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy].

The review is devoted to the contemporary state of the problem of pharmacogenetics of indirect anticoagulants. At present there are data about effects of allele variants of CYP2C9, VKORC1, APOE genes on efficacy and safety of therapy with indirect anticoagulants. Detection of these variants is a perspective way to individualization of therapy with indirect anticoagulants.

Anticoagulants↗
PubMed2005

[Long-term application of warfarin or acenocumarol in patients with fibrillating arrhythmia: the effects compared].

Thromboembolic complications (cerebral infarction and system embolism) are the most threatening ones in patients with ciliary arrhythmia without valvular lesions. Transoesofhageal echocardiography is the method of choice in detection of left atrial auricle thrombosis, which is the main source of thromboembolism in this category of patients. Primary and secondary prevention of thromboembolic complications in patients with ciliary arrhythmia is a topical problem, still remaining unsolved. Administration of indirect anticoagulants, which are the preparations of choice, demands strict doctor's supervision and continuous laboratory monitoring. The study presents authors' own data, based upon the observation of patients treated with either warfarin or acenocumarol. The paper demonstrates equal efficiency of both cumarine anticoagulants. The frequency of haemorrhagic complications after 12-month therapy with either warfarin or acenocumorol in patients with ciliary arrhythmia without valvular lesions was comparable. Warfarin provided more stable level of anticoagulation and thus long-term warfarin therapy was characterized by lower risk of complication.

Acenocoumarol↗
PubMed2004

The importance of D-dimer for the diagnosis of venous thromboses in clinical cardiology.

The aim of the study was to analyze the importance of the rapid assay for D-dimer in the diagnosis of venous thromboses (VT). The study accrued 82 patients. There were 57 (70%) men and 25 (30%) women aged 16 to 86 years. Fifty-three patients were suspected of deep venous thrombosis (DVT) and 29 of pulmonary thromboembolism (PTE). In 49 of the 82 patients, the use of USD, isotope phlebography, x-ray and ventilation-perfusion scintigraphy of the lungs made it possible to verify the diagnosis of VT. In one case, it was verified on autopsy. In 33 patients, the suspicions were rejected. The blood assay for D-dimer was performed using the kit Roche/Diagnostika Stago. The method is based on agglutination of latex particles covered by monoclonal antibodies to D-dimer. Among the 49 patients with a verified diagnosis of VT, D-dimer was positive in 44 (89.8%) and negative in 5 (11.4%) patients. In the group of the 33 patients, in whom the diagnosis of VT was rejected, D-dimer was negative in 26 (78.8%) and positive in 7 (21.8%) patients. Thus, the sensitivity of the assay for D-dimer constituted 89.8% and the specificity 78,8%. The high sensitivity of the assay provides an opportunity of using D-dimer measurement as a screening method in patients suspected of VT. Negative D-dimer is helpful in excluding VT. If D-dimer is positive, the diagnosis should be confirmed by other methods.

Adolescent↗
PubMed2004

[Long-term therapy with anticoagulants in patients with nonvalvular atrial fibrillation (prospective follow-up). Part I. Effect of 12-month therapy with acenocoumarol on content of d-dimer, frequency of thrombosis and parameters of hemodynamics of left auricle].

AIM: To assess frequency of left auricular thrombosis and effect of long-term therapy with acenocoumarol on auricular hemodynamics and system of hemostasis and to elucidate predictors of effective therapy with acenocoumarol in patients with nonvalvular atrial fibrillation. MATERIAL: Patients (n=100) with nonvalvular atrial fibrillation and at least 1 risk factor of thromboembolic complications. METHODS: Transesophageal echocardiography and measurement of blood D-dimer levels were carried out before and after 1 year of acenocoumarol therapy. RESULTS: Initial prevalence of left auricular thrombosis was 75%. The use of acenocoumarol for 12 months resulted in significant reduction of frequency of left auricular thrombosis. This was associated with improvement of parameters of intraatrial hemodynamics and lowering of elevated blood D-dimer levels. Clinical-instrumental predictors of presence of left auricular thrombosis and its dynamics during therapy with acenocoumarol were also elucidated.

Acenocoumarol↗
PubMed2004

[Long-Term Therapy With Indirect Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (Prospective Follow-Up Study). Part II. Effectiveness and Safety].

AIM: To assess efficacy and safety of long-term international normalized ratio (INR) guided therapy with acenocoumarol in patients with nonvalvular atrial fibrillation. MATERIAL: Patients (n=100) with nonvalvular atrial fibrillation and at least 1 risk factor of thromboembolic complications. METHODS: Ischemic strokes, episodes of systemic thromboembolism and hemorrhagic complications were registered during 3 years of treatment with acenocoumarol (target INR 2.0-3.0). RESULTS: Annual rates of ischemic strokes, hemorrhagic complications and major bleeding were 0.7, 14.4 and 1.1%, respectively. No episodes of thromboembolism were registered in patients with history of thromboembolic complications. Basing on data collected predictors of bleeding complications in patients with atrial fibrillation during long term treatment with acenocoumarol were elucidated.

Anticoagulants↗
PubMed2004

[Matrix metalloproteinases, C-reactive protein, and markers of thrombinemia in patients with stable angina and restenoses after percutaneous coronary interventions.].

AIM: To elucidate relationships between blood levels of matric metalloproteinases (MMP), C-reactive protein (CRP), markers of thrombinemia, and development of restenosis after percutaneous coronary interventions (PCI) in patients with stable angina. MATERIAL: Patients (n=78, mean age 55.7+/-0.9 years) after successful PCI. METHODS: MMP-2, MMP-9, CRP, prothrombin fragments 1 and 2, thrombin-antithrombin complex and plasminogen activator inhibitor antigen were measured in blood plasma taken before PCI. Repeat coronary angiography was carried out in 31 patients 6-8 months after PCI. Exercise ECG was used for diagnosis of restenosis in other patients. More than 1 mm ST depression in same ECG leads as before PCI was used as criterion of restenosis. RESULTS: Overall sings of restenosis were found in 28 patients (35.9%). Patients with and without restenosis had similar contents of prothrombin fragments 1 and 2, thrombin-antithrombin complex, plasminogen activator inhibitor antigen and CRP, while patients with restenosis had significantly higher levels of MMP 2 and 9 (r<0.05). At multifactorial analysis level of MMP-9 was independently related to development of restenosis. CONCLUSION: Elevated level of MP-9 has predictive value in relation to development of restenosis.

Angina, Stable↗
PubMed2002

[Antiischemic efficacy of trimetazidine in patients with ischemic heart disease, stable angina pectoris and disturbances of carbohydrate metabolism].

AIM: To compare antiischemic effects of trimetazidine in patients with stable angina pectoris with and without disturbances of carbohydrate metabolism. MATERIAL: Patients with ischemic heart disease, stable class II-III angina pectoris and reproducible positive results of on-treatment exercise tests (n=40, mean age 56.7-/+1.95 years, 37 men) with normal carbohydrate metabolism (group 1, n=20) and with disturbances of carbohydrate metabolism (group 2, n=20). METHODS: All patients in addition to individually selected antianginal therapy were given trimetazidine (60 mg/day) for 2 months. Bicycle exercise tests were repeated after 1 and 2 months. Patient's diaries were used for registration of anginal attacks and nitroglycerine consumption. RESULTS: Addition of trimetazidine was associated with significant (p<0.005) prolongation of exercise duration until 1 mm-ST depression in both groups. Exercise duration was 553-/+10.5 and 555-/+10.2 s (p>0.05) at baseline, 657-/+15.3 and 695-/+10.1 s (p<0.05) after 2 months in groups 1 and 2, respectively. Other effects of trimetazidine in groups 1 and 2 included increases of total work performed during exercise test (by 14 and 22%, respectively), decreases in numbers of patients with ST depression (by 40, p<0.05, and 50%, p<0.05, respectively), numbers of anginal attacks (by 30, p<0.001, and 43%, p<0.001, respectively) and nitroglycerine pills (by 13%, p<0.001 and 51%, p<0.001, respectively). The decrease in supplemental nitroglycerine consumption was significantly more pronounced in group 2 (p<0.0001). There was no significant increment in double product in both groups. CONCLUSION: Antiischemic effect of trimetazidine was greater in patients with angina pectoris and disturbances of carbohydrate metabolism than in similar patients without such disturbances. KEY WORDS. trimetazidine; diabetes, type II, ischemic heart disease; angina pectoris.

Angina Pectoris↗
PubMed2001

[Role of D-dimer in diagnosis of venous thrombosis and embolism].

AIM: To analyze efficiency of semi-quantitative fast D-dimer test in diagnosis of deep vein thrombosis (DVT) and thromboembolism of pulmonary artery (TPA). MATERIAL AND METHODS: The study enrolled 42 patients (26 males and 16 females) aged 25 to 86 years. 30 and 12 of them were suspected to have DVT and TPA, respectively. DVT was verified at ultrasound dopplerography and radionuclide phlebography in 16 of 30 suspects. TPA was verified by x-ray, perfusion scintigraphy of the lungs and at autopsy (one case) in 7 of 12 suspects. D-dimer levels in the blood were measured by latex parts agglutination reaction. The parts were covered with monoclonal antibodies to D-dimer. The reagents were provided by the kit Roche/Diagnostica Stago. RESULTS: The D-dimer test was positive in 20 of 23 DVT patients and negative in 3 cases (13%). Of 19 patients with rejected diagnosis of DVT/TPA the test was negative in 17(89.4%) and positive in 2 patients (10.6%). Thus, sensitivity and specificity of the D-dimer test was 87% and 89.4%, respectively. CONCLUSION: High sensitivity of the test allows to use it in screening for DVT/TPA. Negative D-dimer test rejects DVT, while positive test needs verification by other methods.

Adult↗
PubMed2000

[Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].

AIM: A comparative analysis of the content of the soluble form of cell adhesion protein P-selectin in the blood plasma of patients with acute myocardial infarction (AMI), massive atherosclerosis (MA) and primary pulmonary hypertension (PPH), investigation of the relationship between plasma content of P-selectin and known markers of platelets and endothelial cells activation, preliminary assessment of the prognostic value of P-selectin determination. MATERIALS AND METHODS: This study included 16 patients with AMI, 20 patients with MA, 21 patients with PPH and 18 healthy donors. The follow-up was 1-5 years. End-points in the group of patients with AMI were recurrent acute coronary syndrome and coronary artery by-pass operation, in the group with MA--thrombotic complications (acute coronary syndrome, ischemic stroke) and in the group with PPH--death. P-selectin was measured by ELISA and platelet factor 4 (PF4), thromboxane B2 (TXB2), endothelin-I and stable prostacyclin metabolite 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) by means of commercial ELISA kits. RESULTS: Mean level of P-selectin in blood plasma of patients with AMI (1 day) (361 +/- 18 ng/ml), MA (410 +/- 31 ng/ml) and PPH (627 +/- 83 ng/ml) was increased in comparison with the group of healthy donors (269 +/- 12 ng/ml) (everywhere p < 0.001). In AMI, P-selectin was increased on day 1 only, on days 2, 3 and 10-14 of the disease the level of P-selectin was significantly lower than on day 1 and did not differ from the control level in the group of donors. In patients with MA a significant correlation was detected between plasma content of P-selectin and platelet activation marker PF4 (r = 0.606, P = 0.007) and in patients with PPH between the content of P-selectin and another platelet activation marker TXB2 (r = 0.622, p = 0.013). However, no correlation was found in PPH patients between the content of P-selectin and markers of endothelial activation and/or damage (endothelin-1 and 6-keto-PGF1 alpha). Difference in the concentration of P-selectin in patients with or without end-points during the follow-up period was detected in patients with AMI (353 +/- 14 ng/ml and 451 +/- 24 ng/ml, p = 0.009) and PPH (477 +/- 58 ng/ml and 927 +/- 184 ng/ml, p = 0.017) but not with MA (426 +/- 37 ng/ml and 361 +/- 24 ng/ml, p = 0.295). CONCLUSION: The level of P-selectin in plasma was increased in patients with acute thrombosis (AMI, 1 day) as well as in patients without clinical signs of thrombosis but with a massive injury of the vasculature (MA and PPH). The increase of P-selectin was, presumably, caused by its secretion from activated platelets since its concentration in plasma correlated with platelet concentration but not endothelial activation markers. Preliminary data indicate that blood plasma soluble P-selectin may be considered as a potential prognostic marker in AMI and PPH.

6-Ketoprostaglandin F1 alpha↗